SALT LAKE CITY, Feb. 10, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the upcoming Life Sciences Day on the Hill on February 16, 2022, at the Utah State Capital Building.
It is expected that the conference, sponsored by BioUtah, BioHive, and The Utah Life Sciences Innovation Caucus, will provide the Company with opportunities to showcase its contributions to Utah's life science industry and introduce its innovations to an audience of State legislators and industry leaders.
Dwight Egan, CEO of Co-Diagnostics, remarked, "Co-Diagnostics has sold over 30 million of our suite of high-quality COVID-19 PCR test products around the world since becoming the first U.S.-based company to receive a CE-marking for a COVID-19 test, followed by our Emergency Use Authorization from the FDA. February 10 marks an important Company milestone as we commemorate two years from our first sale of COVID-19 tests. We are excited for the opportunity to exhibit our products to such an influential audience and share what we believe the future has in store for Co-Diagnostics, including the Company's upcoming point-of-care and at-home rapid PCR diagnostics platform."
Attendees interested in learning more about the Company and its products are invited to visit the Company's booth at the Utah State Capital Rotunda between 7:00 AM and 10:00 AM.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a state-of-the-art diagnostics technology. The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) that are subject to a number of risks and uncertainties. Risks and uncertainties that may cause such differences include, among other things: our products may not prove to be as effective as other products currently being commercialized or to be commercialized in the future by competitors; risks inherent in manufacturing and scaling up to commercial quantities while maintaining quality controls; the uncertainties inherent in new product development, including the cost and time required to gain regulatory clearance for such product and to commercialize such product(s);and, market acceptance of our products once commercialized. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations, and beliefs. There can be no assurance that any of the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties, a discussion of which can be found in the Risk Factors disclosure in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 25, 2021, and in our other filings with the SEC. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.